Anti-SARS-CoV-2 Monoclonal Antibodies

Last Updated: August 04, 2021

Table A. SARS-CoV-2 Variants of Concern and Interest and Susceptibility to Anti-SARS-CoV-2 Monoclonal Antibodies

Table A. SARS-CoV-2 Variants of Concern and Interest and Susceptibility to Anti-SARS-CoV-2 Monoclonal Antibodies
WHO Label Pango Lineage CDC Variant Class Notable Mutations Bamlanivimab Plus Etesevimab Casirivimab Plus Imdevimab Sotrovimab
In Vitro Susceptibilitya Activityb In Vitro Susceptibilitya Activityb In Vitro Susceptibilitya Activityb
Alpha B.1.1.7 VoC N501Y No change Active No change Active No change Active
Beta B.1.351 VoC K417N, E484K, N501Y Marked change Unlikely to be active No changec Active No change Active
Gamma P.1 VoC K417T, E484K, N501Y Marked change Unlikely to be active No changec Active No change Active
Delta B.1.617.2 VoC L452R Modest changed Likely to be active No change Active No change Active
Epsilon B.1.429/B.1.427 VoI L452R Modest changed Likely to be active No change Active No change Active
Iota B.1.526 VoI E484K Modest changed Likely to be active No changec Active No change Active